Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.91 USD
Change Today -0.24 / -0.34%
Volume 2.4M
BAX On Other Exchanges
Symbol
Exchange
New York
Berlin
SIX Swiss Ex
Mexico
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Open
$69.75
Previous Close
$70.15
Day High
$70.19
Day Low
$69.60
52 Week High
07/23/14 - $77.31
52 Week Low
02/20/15 - $65.94
Market Cap
38.0B
Average Volume 10 Days
2.9M
EPS TTM
$4.49
Shares Outstanding
543.5M
EX-Date
03/9/15
P/E TM
15.6x
Dividend
$2.08
Dividend Yield
2.97%
Current Stock Chart for BAXTER INTERNATIONAL INC (BAX)

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $755.0K
Corporate Vice President and President of Bio...
Total Annual Compensation: $833.8K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX) Key Developments

Baxter International Inc. Presents Additional Data from the Phase Iii Clinical Trial of BAX 111

Baxter International Inc. presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1 The data were presented as an Abstract of Distinction during an oral session at the 2015 Scientific Symposium of the Hemostasis and Thrombosis Research Society (HTRS) in New Orleans, La. and expand on the topline data first disclosed in 2014. The trial met its primary efficacy endpoint defined by the number of patients who achieved treatment success for control of bleeding episodes. All patients treated in the full analysis set (N=22) experienced a 100% treatment success rating based on a 4-point efficacy rating scale, comparing estimated number of infusions needed to treat the bleeding episodes to the actual number of infusions administered. Efficacy for all treated bleeds (N=192) was rated excellent (96.9%) or good (3.1%), including major bleeds (6 excellent and 1 good). The median number of infusions required to treat bleeding events in the trial was 1 and the majority of events (81.8%) were resolved with a single infusion. The multi-center, open-label clinical trial was designed to assess the safety, efficacy and pharmacokinetics of BAX 111 among patients with severe von Willebrand disease aged 18 to 65 years. Bleeding events that occurred during the study were treated with rVWF (40-60 IU/kg; up to 80 IU/kg for major bleeds) initially together with rFVIII and subsequently alone if hemostatic FVIII levels were maintained. rVWF pharmacokinetic (PK) parameters were determined with and without rFVIII and repeated after 6 months for rVWF; these analyses found that rVWF PK was not affected by administration together with rFVIII. The recombinant technology used to produce BAX 111 avoids certain protein maturation processes that typically occur with plasma fractionation. This preserves large functional units known as ultra large multimers, which have been shown to be efficient in clot formation and FVIII stabilization.

Coherus BioSciences and Baxter International Amend CHS-0214 Collaboration Agreement

Coherus BioSciences and Baxter International have made amendments to certain financial terms of their collaboration agreement that was signed to develop and commercialise CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Both firms signed the contract in August 2013. Under the amended contract, certain existing milestones and funding obligations have been revised, and the deal has been expanded to include select pre-commercialisation activities. The received milestone payments are likely to exceed the earlier Baxter funding obligations by around USD12 million.

Baxter International Inc. Submits New Drug Application to Japan’s Ministry of Health, Labour and Welfare for the Approval of BAX 855

Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A. The submission follows the filing to the United States Food and Drug Administration (FDA) in late 2014 and is based on positive results from a prospective, global, Phase 3 study of 137 previously treated patients (PTP). The results, presented during the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in February 2015, demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median annual bleed rate (ABR) as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse reaction was headache (3 patients). Baxter continues to advance a continuation study for patients who completed the pivotal trial and a Phase 3 study among previously treated patients under the age of 12 with severe hemophilia A. Once the pediatric study has been completed, the company expects to file for marketing authorization with the European Medicines Agency in 2016 and intends to seek post-approval label expansion in the U.S. for previously-untreated pediatric patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $69.91 USD -0.24

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,897 JPY -19.50
Kimberly-Clark Corp $106.78 USD -0.90
Mylan NV $69.82 USD +2.98
Stryker Corp $92.50 USD +0.32
Takeda Pharmaceutical Co Ltd ¥6,095 JPY +69.00
View Industry Companies
 

Industry Analysis

BAX

Industry Average

Valuation BAX Industry Range
Price/Earnings 19.7x
Price/Sales 2.3x
Price/Book 4.7x
Price/Cash Flow 15.2x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.